946 results on '"Baiocchi, Robert A."'
Search Results
152. Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma
153. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation
154. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma
155. IFN-γ gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice
156. Stress-associated changes in the steady-state expression of latent Epstein–Barr virus: Implications for chronic fatigue syndrome and cancer
157. Additional file 1: of Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro
158. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy
159. A Human CD34(+) Subset Resides in Lymph Nodes and Differentiates into CD56brightNatural Killer Cells
160. Epstein–Barr virus- and human herpesvirus 8-associated primary cutaneous plasmablastic lymphoma in the setting of renal transplantation
161. Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus–Positive Lymphoproliferative Disorder
162. The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2
163. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i. p. with EBV-seropositive human peripheral blood lymphocytes
164. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder
165. PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma
166. Restoring Functional Deficits in Older Adults with Hematologic Malignancy
167. Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials
168. PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity
169. Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma
170. Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial
171. Targeting Hypersumoylation in Mantle Cell Lymphoma
172. Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
173. A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes
174. Spinal Cord Toxicity from Intrathecal Chemotherapy: A Case with Clinicopathologic Correlation
175. Abstract LB-102: Extranodal natural killer/T cell lymphoma (ENKTL) exhibits an unprecedented degree of global DNA hypermethylation, providing a potent targeted therapy in vivo
176. A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas.
177. Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β proliferative signaling
178. Modulation of immune checkpoint molecule expression in mantle cell lymphoma
179. Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma
180. Macrophage Activation Syndrome Versus Hemophagocytic Lymphohistiocytosis: A Diagnostic Dilemma in a Patient With Still’s Disease and Epstein-Barr Virus Viremia
181. Ultra Low Dose Interleukin-2 Therapy Promotes a Type 1 Cytokine Profile In Vivo in Patients with AIDS and AIDS-associated Malignancies
182. Endogenous Production of Interleukin 15 by Activated Human Monocytes Is Critical for Optimal Production of Interferon-gamma by Natural Killer Cells In Vitro
183. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
184. New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
185. 219 - Clinical Experience of Tabelecleucel in Patients with EBV+ Primary (PID) or Acquired Immunodeficiency (AID) Associated Lymphoproliferative Disease
186. Generation of monocyte-derived tumorassociated macrophages using tumorconditioned media provides a novel method to study tumor-associated macrophages in vitro.
187. Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer
188. Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
189. Exploring PRMT5 As a Potential Therapeutic Target in Canine Lymphomas
190. PRMT5 Is Upregulated in Activated T Cells and Is a Novel Therapeutic Target for Acute Gvhd
191. BZLF1-DEC205 Fusion Protein Enhances EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative Disease
192. Erdheim Chester disease in a patient with Burkitt lymphoma: a case report and review of literature
193. PU.1 and epigenetic signals modulate 1,25‐dihydroxyvitamin D 3 and C/EBPα regulation of the human cathelicidin antimicrobial peptide gene in lung epithelial cells
194. Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
195. Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone
196. Abstract 4691: Role of select T helper cell subsets in the development of Epstein-Barr virus-driven lymphoproliferative disease
197. Abstract 1880: Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the canine model of non-Hodgkin lymphoma
198. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy
199. Arginine methylation drives inflammatory T cell responses and autoimmunity
200. Oral Mycosis Fungoides: A Report of Three Cases and Review of the Literature
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.